Published in Eur J Neurosci on March 01, 2004
Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems. Pharmacol Rev (2016) 1.02
LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. Front Mol Neurosci (2014) 1.01
The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence. Pharmacol Ther (2013) 0.98
Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands. Naunyn Schmiedebergs Arch Pharmacol (2006) 0.93
Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic Gi/o protein linked pathways. Br J Pharmacol (2007) 0.90
Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.88
The NOP (ORL1) receptor antagonist Compound B stimulates mesolimbic dopamine release and is rewarding in mice by a non-NOP-receptor-mediated mechanism. Br J Pharmacol (2004) 0.81
Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux. Br J Pharmacol (2005) 0.81
Opioid modulation of GABA release in the rat inferior colliculus. BMC Neurosci (2004) 0.76
Receptor mediation and nociceptin inhibition of bradykinin-induced plasma extravasation in the knee joint of the rat. Inflamm Res (2009) 0.75
Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity. Sci Rep (2017) 0.75
Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature (2012) 2.96
Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur J Biochem (2002) 1.99
The tachykinin peptide family. Pharmacol Rev (2002) 1.82
Brain-derived neurotrophic factor mRNA and protein are targeted to discrete dendritic laminas by events that trigger epileptogenesis. J Neurosci (2004) 1.51
Dmt and opioid peptides: a potent alliance. Biopolymers (2003) 1.40
Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties. J Med Chem (2002) 1.40
The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory pain. Proc Natl Acad Sci U S A (2009) 1.24
Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore. J Med Chem (2002) 1.23
Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc Natl Acad Sci U S A (2009) 1.18
MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J Pathol (2011) 1.15
[Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol (2002) 1.14
Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation. J Biol Chem (2006) 1.13
Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem (2007) 1.12
Interaction of sweet proteins with their receptor. A conformational study of peptides corresponding to loops of brazzein, monellin and thaumatin. Eur J Biochem (2004) 1.11
Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor. Med Res Rev (2010) 1.09
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies. J Pharmacol Exp Ther (2007) 1.09
Synthesis and biological activity of human neuropeptide S analogues modified in position 5: identification of potent and pure neuropeptide S receptor antagonists. J Med Chem (2009) 1.08
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J Neurosci (2005) 1.06
Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist. Peptides (2007) 1.05
In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S. J Pharmacol Exp Ther (2008) 1.05
Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur J Pharmacol (2004) 1.04
Solution structure of amyloid beta-peptide (25-35) in different media. J Med Chem (2004) 1.04
Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures. J Neuroinflammation (2010) 1.02
6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem (2006) 1.02
UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor. CNS Drug Rev (2005) 1.01
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels. Neurobiol Dis (2011) 1.01
New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem (2006) 1.00
Triazine compounds as antagonists at Bv8-prokineticin receptors. J Med Chem (2008) 0.99
Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus. Epilepsia (2011) 0.97
Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem (2006) 0.97
Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. Peptides (2010) 0.97
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. Brain (2012) 0.96
Activation of DOR attenuates anoxic K+ derangement via inhibition of Na+ entry in mouse cortex. Cereb Cortex (2008) 0.96
Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism. J Med Chem (2004) 0.96
Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic. J Med Chem (2004) 0.96
Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore. ACS Chem Neurosci (2010) 0.96
A pathogenetic hypothesis of Unverricht-Lundborg disease onset and progression. Neurobiol Dis (2006) 0.95
Interaction of calmodulin with the phosphofructokinase target sequence. FEBS Lett (2004) 0.95
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J Neurosci (2004) 0.95
Synthesis and biological activity of human neuropeptide S analogues modified in position 2. J Med Chem (2008) 0.95
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies. J Pharmacol Exp Ther (2007) 0.95
A new ligand for the urotensin II receptor. Br J Pharmacol (2002) 0.95
Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein G alpha qi5. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.95
Conformation-activity relationship of neuropeptide S and some structural mutants: helicity affects their interaction with the receptor. J Med Chem (2007) 0.94
Functional antagonism between nociceptin/orphanin FQ (N/OFQ) and corticotropin-releasing factor (CRF) in the rat brain: evidence for involvement of the bed nucleus of the stria terminalis. Psychopharmacology (Berl) (2007) 0.94
In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. Peptides (2007) 0.93
Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons. J Neurosci (2002) 0.93
Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists. J Med Chem (2009) 0.92
Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24. Eur J Pharmacol (2009) 0.92
Conversion of the potent delta-opioid agonist H-Dmt-Tic-NH-CH(2)-bid into delta-opioid antagonists by N(1)-benzimidazole alkylation(1). J Med Chem (2005) 0.91
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J Neurosci (2007) 0.90
Pharmacological characterization of the nociceptin receptor which mediates reduction of alcohol drinking in rats. Peptides (2002) 0.90
Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiol Dis (2008) 0.90
In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803). Br J Pharmacol (2006) 0.89
Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. J Neurochem (2004) 0.89
Pharmacological profile of nociceptin/orphanin FQ receptors. Clin Exp Pharmacol Physiol (2002) 0.89
Synthesis and opioid activity of N,N-dimethyl-Dmt-Tic-NH-CH(R)-R' analogues: acquisition of potent delta antagonism. Bioorg Med Chem (2003) 0.89
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels. J Neurochem (2011) 0.89
Unique high-affinity synthetic mu-opioid receptor agonists with central- and systemic-mediated analgesia. J Med Chem (2003) 0.89
Pro-nociceptin/orphanin FQ and NOP receptor mRNA levels in the forebrain of food deprived rats. Brain Res (2002) 0.89
Conformationally constrained opioid ligands: the Dmt-Aba and Dmt-Aia versus Dmt-Tic scaffold. Bioorg Med Chem Lett (2008) 0.89
Structure-activity study at positions 3 and 4 of human neuropeptide S. Bioorg Med Chem (2008) 0.88
Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm Res (2008) 0.88